Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Cost Effectiveness and Resource Allocation

Fig. 2

From: Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK

Fig. 2

a Random-effects meta-analysis of tiotropium comparator trials. b Probabilistic sensitivity analysis: net benefit acceptability curves for UMEC/VI compared with tiotropium. CI confidence interval, ES effect size, IND indacaterol, TIO tiotropium, UMEC/VI umeclidinium bromide/vilanterol. DB2113374 and DB2113360 [11]; ZEP117115 [12]. a Effect size (ES) represents increment in FEV1 (ml) of UMEC/VI compared to tiotropium. b Each line on the graph represents probability of acceptance of UMEC/VI compared to tiotropium under a particular scenario at multiple thresholds of willingness to pay

Back to article page